Introduction: There is evidence of increasing levels of pre-treatment HIV drug resistance
Introduction
After approximately two decades of combination antiretroviral therapy (ART), the global response to the human immunodeficiency virus (HIV) is threatened by the development of HIV drug resistance (HIVDR). 1 Pre-treatment drug resistance (PDR) refers to the presence of drug resistance in a person initiating or re-initiating ART, and can therefore be a combination of transmitted and acquired drug resistance (ADR). Such resistance is considered the best indicator to guide the selection of effective first-line ART regimens. [2] [3] [4] While the levels of PDR in low-and middle-income countries have been low to moderate historically, there are concerns over increasing levels, given the rapid expansion in ART access and the persistent high incidence of new HIV infections. 5 Once PDR exceeds 10%, modelling suggests that in Africa, HIVDR could account for almost half a million new infections, and $6.5 billion in additional ART costs between 2016 and 2030. 6 As part of its coordinated approach to prevent, monitor and respond to the emergence of HIVDR, the World Health Organization (WHO) recommends surveys of PDR. 4 As more people receive ART and develop ADR, the risk of transmission of drug-resistant HIV increases. 7 The presence of PDR can lead to inadequate virologic suppression on ART and further accumulation of drug resistance mutations, 8, 9 and as a result, the levels of PDR have to be continually monitored to ensure the effective use of ART. At this critical juncture in the global response to HIV, with scale-up of universal test-and-treat and preexposure prophylaxis (PrEP) for HIV prevention, 10 it is important to understand the current epidemiology of PDR in high-prevalence settings.
South Africa has the largest ART programme in the world, with approximately 3.9 million people on treatment as of August 2017. 11 Generally, low levels of PDR have been documented in the country, 12, 13 but there is recent evidence of higher levels, which raises concern over the continued effectiveness of first-line non-nucleoside reverse-transcriptase inhibitor (NNRTI)-based ART regimens. [14] [15] [16] The evidence of increasing PDR is in the context of a growing number of people with virological failure on ART and delayed switching to second-line ART, creating an expanding pool of those with ADR. 17 In this paper, we present This paper has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof.
estimates of PDR from two population-based studies in KwaZulu-Natal Province (KZN), South Africa.
Materials and Methods

Setting
The Africa Health Research Institute (AHRI) has conducted longitudinal population-based HIV surveillance in the uMkhanyakude District Municipality, northern KZN since 2003
(Study A, Figure 1 ). 18 All individuals 15 years and older in a population of approximately 65,000 resident members are invited to provide dried blood spot (DBS) specimens on an annual basis. For this study, viral reverse transcription PCR was performed on the DBS specimens of the participants with a positive HIV enzyme-linked immunosorbent assay (ELISA) in 2013 or 2014, who had a DBS HIV ribonucleic acid (RNA) ≥10,000 copies/mL. PCR and sequencing were also attempted on some DBS specimens with HIV RNA <10,000 copies/mL, but this was not pursued as the rate of successful amplification was low. We excluded sequences obtained from participants with documented ART initiation prior to the date of specimen collection. Information about ART use was obtained through linkage of the population surveillance data with routine HIV programme data. 19 This did not include information about prior use of antiretrovirals for preventing mother-to-child transmission (pMTCT). We estimated the date of HIV infection using the midpoint between the last negative test date and the first positive test date, and estimated the duration of infection in months, by calculating the time between the estimated date of infection and the sample collection date, as described previously. This paper has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof.
9812 individuals were eligible and consented to participate. HIV ELISA was performed on the peripheral blood specimens of the participants, 22 and sequencing was performed on the plasma specimens from participants with positive HIV serology and plasma HIV RNA ≥1000 copies/mL. 21 For the analysis, we excluded sequences from those who self-reported any prior ART use (for treatment or pMTCT). Details on the timing of recruitment and ascertainment of ART status for the two population-based studies, are provided in Supplementary data.
Laboratory methods and data analysis
Genotypic drug resistance testing of the HIV-1 reverse transcriptase (RT) and protease (PR)
genes was done on stored specimens by Sanger sequencing on an ABI 3130 Genetic
Analyzer (Applied Biosystems, Foster City, CA) using previously described methods. 24 Sequence quality and coverage were assessed using the Calibrated Population Resistance (CPR) tool (http://cpr.stanford.edu/cpr.cgi). Sequences that had quality concerns, such as stop codons, or that did not cover all possible surveillance drug resistance mutation (SDRM) positions, were excluded. We included participants with complete RT sequences, with or without the PR sequence.
PDR was determined by detecting SDRMs with the CPR tool using the WHO 2009 SDRM list. 25, 26 The results were used to estimate the levels of overall and drug class-specific resistance for each study, with the data being analyzed using STATA version 15.1 (StataCorp, College Station, TX) and SAS version 9.4 (SAS Institute, Cary, NC). The chisquare test was used to establish any difference in PDR prevalence across the years, within each study, with a Rao-Scott chi-square test being used for study B to adjust for the survey design. Logistic regression analysis was performed to explore associations between PDR and individual participant characteristics for each study (i.e. sex, age, HIV RNA, and for study A; the estimated duration of infection), and accounted for the survey sample design in study B. Where appropriate, analyses for study B were conducted by applying sampling weights and using survey procedures. The sampling weights adjusted for non-equal probabilities of selection associated with the complex survey design, and for non-response across age and gender categories. 20 The confidence intervals were calculated using Wald sequences generated previously from the AHRI surveillance population. 14, 17, 27 To avoid cluster formation due to convergent evolution under ART pressure, codon positions associated with drug resistance mutations were removed from the alignment.
28
A maximum likelihood (ML) phylogenetic tree was constructed using FastTree2, 29 and
cluster support was assessed with Shimodaira-Hasegawa approximate likelihood ratio test (SH-aLRT) with 1000 pseudo-replicates. HIV-1 transmission clusters were identified from the ML tree using the ClusterPicker software version 1. This paper has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof.
Overall, 1841 had complete RT and PR sequences, and four had only the complete RT sequence. The characteristics of the participants included in the analysis are summarised in Table 1 .
The estimated prevalence of PDR was 9.2% (95% confidence interval (CI) 7.0-11.7) for study A and 11.0% (95% CI 8.9-13.2) for study B. The estimated prevalence of NNRTI PDR was 7.5% (95% CI 5.6-9.9) for study A and 9.2% (95% CI 7.2-11.3) for study B. There was no evidence of an increase in overall PDR or NNRTI PDR across the two years in either study ( Figure 3 ). The estimated prevalence of PDR was higher for women than men in both studies: 9.9% vs. 7.1% for study A (odds ratio (OR) 1.45, 95% CI 0.73-2.87); and 13.6% vs.
8.3% for study B (OR 1.73, 95% CI 1.06-2.81) ( Table 3 and Supplementary Figure S1 ).
The prevalence of PDR peaked at 17.0% (95% CI 11.9-22.1) in women aged 25-34 years (Supplementary Table S1 ). There was no strong evidence of an association between PDR and age or HIV RNA in either study (see Table 3 ). In study A, the prevalence of PDR was lower in those with an estimated duration of infection ≤24 months than in those with estimated duration >24 months (3.0% vs. 8.6%), but the analysis was limited by small numbers with recent infection (n=66) (see Table 3 ).
Of all 1845 sequences across the two studies, 212 (11.5%) had at least one SDRM. The frequency of individual SDRMs by study year is displayed in Table 2 . Overall, 182/1845 (10.0%) had NNRTI mutations, 59/1845 (3.2%) had nucleoside reverse-transcriptase inhibitor (NRTI) mutations, and 23/1841 (1.2%) had protease inhibitor (PI) mutations (Table 2 ). Of those with SDRMs, 162 (76.4%) had single class resistance, 48 (22.6%) dual class resistance, and two (1.0%) triple class resistance. The most frequently observed SDRM was the NNRTI mutation K103NS, occurring in 139 participants (7.5% of all participants, or 65.6% of those with SDRMs). In 100 participants (47.2% of those with drug resistance mutations), the K103NS mutation was the only SDRM detected (Supplementary   Table S2 ), which lists the most frequently observed patterns of mutations).
The most common NRTI mutation was M184VI (2.4%), and in almost all cases (43 of 44) it was detected in combination with at least one NNRTI mutation, while in half the cases (22 of 44) with other NRTI mutations. The K65R mutation associated with tenofovir (TDF)
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resistance was detected in 11 participants overall (0.6%), with no evidence of an increase across the two years in either study. Of the 23 with PI mutations, 20 had a single PI mutation. The most common PI mutation was the M46IL mutation, occurring in 18
participants. Two participants with four or more PI mutations had similar patterns of PI resistance (M46I, I54V, L76V, V82A), with one participant having in addition the L90M mutation. In both cases, there was triple class resistance with NRTI mutations (M184V, L74V) and an NNRTI mutation (K103S).
From the phylogenetic analysis, we identified 25 transmission clusters with individuals harbouring at least one PDR mutation in common (Supplementary Figure S2) . In total, 57 individuals were grouped in these transmission clusters, 56% (32/57) were from studies A The results from the AHRI longitudinal population surveillance suggest a continued trend of steadily increasing PDR since 2010. 14 In the HIPSS cross-sectional survey, the level of NNRTI PDR was close to 10%, the current threshold at which the WHO recommends urgent public health action. 
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quality of HIV prevention, treatment and care, and should prompt consideration of appropriate public health measures to ensure the long-term sustainability of ART.
The timing of this increase in levels of PDR is consistent with other findings from subSaharan Africa, where PDR rose to moderate levels about ten years into ART scale-up.
31,32
To some extent, our findings are consistent with a nationally-representative survey conducted in South Africa in 2013-2014, which estimated the prevalence of PDR at 9.0%
and NNRTI PDR at 8.3% nationally. 15 The two sites are similar in terms of demographics, HIV epidemiology and HIV care cascades. 22, 33 However, there were some differences in the study populations, particularly the higher HIV RNA levels in study A due to the use of DBS samples for sequencing, as the amplification success rate reduces at lower HIV RNA levels (<10,000 copies/mL) in DBS samples. 34 Using DBS samples which have a higher HIV RNA requirement for genotyping, could have resulted in an underestimation of the levels of resistance for study A, as drug-resistant viruses have a lower replicative capacity than the wild-type virus, which could result in lower HIV RNA levels, although this may depend on the specific profile of mutations. 35, 36 Another difference between the two studies was the method used to determine prior ART use. It is possible that the self-report of ART use in the HIPSS (study B) was less reliable than linkage to health service records as a method for uncovering current or prior use of ART. Significant undisclosed ART use has been documented in other population-based surveys, 37, 38 and if people on ART were inadvertently included in the sample for this analysis, then the levels of PDR from the HIPSS (study B) may be overestimated. Given these difficulties, it is possible that future studies should include testing for antiretroviral drug levels to determine the true ART status. Although the PDR prevalence was somewhat higher in women in both studies, the difference was not as marked as that reported for a number of recent national PDR surveys. 5 In addition, we did not observe a clear gradient in PDR across age groups, unlike a recent study in Kenya, 39 although it is notable that PDR levels were particularly high in young women, the group with the highest HIV incidence in these populations.
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The rapid expansion of ART coverage has been a considerable achievement in South Africa, having resulted in substantial gains in life expectancy. 40, 41 Routine viral load (VL) monitoring to guide ART switches has been incorporated into the treatment programme since the start of ART roll-out. Despite this, implementation remains inconsistent, and the results are often not appropriately acted upon. [42] [43] [44] [45] With the resulting delays in switching to second-line ART regimens, people spend more time viraemic and at risk of accumulating drug resistance. 17 With the growing caseloads of people on first-line ART, this suggests that there will be an expanding pool of people with ADR, creating conditions for an increase in the transmission of HIVDR. 46 Our findings lend support to calls for increased focus on quality improvement within the HIV treatment programme, particularly with respect to adherence support, routine virologic monitoring and timely ART switching.
44,45
Overall, around one in ten participants had at least one NNRTI SDRM, the most frequent mutation being K103NS, which is consistent with the national PDR survey, 15 and is the most common NNRTI mutation documented in the context of ADR on first-line ART. 47 The persistence of this mutation in the absence of drug pressure 48 may increase the chance of onward transmission, and the levels documented here raise concern about the continued effectiveness of efavirenz (EFV) and nevirapine in first-line regimens. The levels of NRTI resistance were relatively low, and the estimated prevalence of key SDRMs associated with TDF resistance (K65R and K70E) was below 1% in both studies. This was also consistent with the national survey that estimated the prevalence of K65R at 1.4%. 15 At the time of these studies, TDF had still only been in widespread use in first-line ART regimens for under five years, so continued vigilance is required, especially as high levels of K65R have been documented in those with ADR on first-line ART, and with evidence supporting the transmissibility of K65R variants. 47,49 However, these findings provide reassurance for now about the place of TDF in first-line ART and PrEP regimens, 50 and although the levels of PI resistance were low, the two instances of multiple major PI mutations and triple class resistance raise some concern. The information available from the public sector health records suggested that neither had been exposed to ART. However, multiple major PI mutations and triple class resistance suggest the two individuals had prior use of ART.
Therefore, these findings should be interpreted with caution, given the potential for data This paper has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof.
Our findings should be interpreted with certain limitations, as the two studies were not conducted as formal drug resistance surveys for pre-treatment or transmitted drug resistance. Although population-based studies present challenges in accurately determining current and prior ART use, they might have some advantages over facilitybased HIVDR surveys in that they include a more broadly representative sample of HIVpositive people in the population, including people not accessing health care. However, this representativeness is diminished if there are low levels of consent in population-based surveys, as seen in the AHRI surveillance. There was substantial attrition in the laboratory processes, particularly with the DBS specimens, and we cannot be certain that the participants whose virus was successfully sequenced were representative of all eligible ART-naïve people in the study populations. Our capacity to uncover linked drug resistant transmissions was limited by the relatively low coverage of people living with HIV in the study areas, particularly for study B. Finally, as these studies were in geographicallyrestricted populations, these results should not be taken to be representative of the entire province of KZN, or of South Africa more generally.
In conclusion, the high levels of PDR documented here highlight the need for renewed focus on improving the quality in HIV prevention, treatment and care. In particular, the systems for routine VL monitoring for people on ART and switching to second-line ART should be strengthened. These findings should be interpreted together with results of the national drug resistance survey to inform the need for modification of the standard firstline ART regimen or the introduction of other public health measures to prevent the spread of drug resistance.
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Study B
In 2014, samples were collected between 7 January and 12 December, and the median date of sample collection was 26 August 2014, whilst in 2015, samples were collected between between 4 January and 6 December, and the median date of sample collection was 28 April 2015.
In the HIV Incidence Provincial Surveillance System (HIPSS), the survey included questions about antiretroviral use, which were asked to any participant who reported being HIV positive. The first question asked was 'Has a doctor or nurse told you that you need to take From these questions, we determined whether there had been any use of antiretrovirals for treatment or pMTCT prior to the date of sample collection.
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